Fresenius SE & Co. KGaA

Investor Presentation • Jul 30, 2015

Conference Call – Q2/2015 Results

July 30, 2015

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Fresenius Group: Financial Results

		Q / 2 1 5	/ H 1 1 5
S l a e s	h G t r o w c c G h l t t t r o w a c u a r a e s	€ 6 9 6 4 m , 1 3 % 2 6 %	€ 1 3 2 9 4 m , 1 3 % 2 % 5
1 E B I T	h G t o c c r w h l G t t t r o w a c u a r a e s	€ 9 7 1 m 1 2 % 2 8 %	€ 8 2 2 1 m , 1 5 % 3 0 %
1 N i t e n c o m e	G h t o c c r w h l G t t t o a c a a e s r w u r	€ 3 5 0 m 2 2 % 3 5 %	€ 6 4 2 m 9 % 1 3 2 %

1Before special items

For a detailed overview of special items please see the reconciliation tables on slides 26-27.

Conference Call – Q2/15 Results, Fresenius SE & Co. KGaA, Investor Relations © Copyright, July 30, 2015

Fresenius Group: Financial Results by Business Segment

	Q / 2 1 5	G h t r o w Q Y Y 2 o	/ H 1 1 5	G h t r o w H Y Y 1 o
S l a e s E B I T	\$ U S 4 1 9 9 m , \$ U S 5 4 7 m	9 % % 2 -	\$ U S 8 1 5 9 m , \$ U S 1, 0 5 1 m	1 0 % % 5
l S a e s 1 E B I T	€ 1, 5 3 8 m € 3 1 4 m	2 3 % % 5 0	€ 2 9 3 2 m , € 5 7 1 m	1 9 % % 3 9
l S a e s 1 E B I T	€ 1, 3 8 3 m € 6 0 1 m	7 % 8 % 1	€ 2 7 7 4 m , € 3 0 7 m	1 0 % 2 3 %
l S a e s E B I T	€ 2 5 5 m € 9 m	% 2 3 0 %	€ 4 6 3 m € 6 1 m	% 1 6 % 7

1Before special items

For a detailed overview of special items please see the reconciliation tables on slides 26-27.

Conference Call – Q2/15 Results, Fresenius SE & Co. KGaA, Investor Relations © Copyright, July 30, 2015

Q2 Business Segment Update

Accelerated sales and EBIT growth

Regional development

North America

• IV drug shortages persisting
• 5 product launches YTD
• Expected 2015 organic sales growth range now 8% to 12%

Europe

• Continued strong business momentum with 5% organic sales growth
• Timing of contract manufacturing orders suggest slightly lower H2 sales growth

Emerging Markets

• Organic sales growth expected to accelerate in H2, FY organic sales growth now forecast to reach high single digits
• Sale of €100 m Australian oncology compounding activities to streamline business, transaction expected to be closed by year-end

Kabi efficiency program

€100 m efficiency program fully on track; €30 m booked in Q2, remainder of approx. €60 m back-loaded in 2015

Q2 Business Segment Update

Hospital business fully on track

• 100 bps sequential margin expansion reflects continued successful integration of acquired Rhön hospitals
• Fully on track to meet full-year guidance

Strong organic sales growth

• Project business drives organic sales growth (31% organic sales growth), continued strong sales growth momentum in service business (11% organic sales growth)
• Fully on track to meet full-year guidance

Group Financials Q2/15 − Outlook 2015

Fresenius Group: Profit and Loss Statement

		G h t r o w	Q 2 Y Y o		G h t r o w	H 1 Y Y o
€ m	Q / 2 1 5	l t a c u a t r a e s	t t c o n s a n t r a e s	/ H 1 1 5	l t a c u a t r a e s	t t c o n s a n t r a e s
l S a e s	6 9 6 4 ,	2 6 %	1 3 %	1 3 2 9 4 ,	2 % 5	1 3 %
1 E B I T	9 7 1	2 8 %	2 % 1	8 2 2 1 ,	3 0 %	% 1 5
N i t t t e n e e s r	1 6 5 -	1 4 % -	1 % -	3 3 0 -	1 7 % -	4 % -
1 I t n c o m e a x e s	2 3 4 -	8 % 1 -	2 % -	4 4 1 -	3 3 % -	6 % 1 -
2 N i t e n c o m e	3 5 0	3 5 %	2 2 %	6 4 2	3 2 %	1 9 %

1 Before special items

2Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items

For a detailed overview of special items please see the reconciliation tables on slides 26-27.

Fresenius Kabi: Strong EBIT Growth

€ m	/ Q 2 1 5	G h t r o w Q 2 Y Y o	/ H 1 1 5	G h t r o w H 1 Y Y o
E o p e u r M i a g n r	9 1 1 7. 0 %	1 2 % b 1 5 0 p s	1 7 4 1 6. 5 %	1 6 % b 1 9 0 p s
h N A i t o r m e r c a M i a g n r	2 2 7 4 1. 0 %	6 3 % b 2 9 0 p s	4 0 3 3 9 3 %	4 1 % b 1 0 0 p s
f / / f i i i i i i A P L t A A s a a c c a n m e c a c a r r - M i a r g n	0 7 1 5. 5 %	9 % 1 -7 0 b p s	3 3 1 1 5. 6 %	2 3 % 1 0 b p s
C d C & R D t t o r p o r a e a n o r p o r a e	7 4 -	% 7 -	3 9 1 -	% 5 -
l T E B I T t o a t t t a c o n s a n c u r r e n c y M i a r g n	3 1 4 2 0 4 %	% 5 0 2 6 %	5 7 1 1 9 5 %	% 3 9 1 8 %

EBIT before special items

For a detailed overview of special items please see the reconciliation tables on slides 26-27.

Fresenius Helios: Strong EBIT margin increase

€ m	/ Q 2 1 5	G h t r o w Q 2 Y Y o	/ H 1 1 5	G h t r o w H Y Y 1 o
T l l t o a s a e s	1 3 8 3 ,	% 7	2 7 7 4 ,	% 1 0
E B I T
b l h d l f l E i i i i t t s a s e c n c p o o o r M i a g n r	1 5 5 % 1 1. 7	1 5 % 2 0 b 1 p s	2 9 8 % 1 1. 5	2 0 % 6 0 b 1 p s
A i i i t c q s o n s u	5		9
( l i d i 1 ) t < c o n s o a o n y r M i a g n r	7. 9 %		4 7 %
T l E B I T t o a	1 6 0	1 8 %	3 0 7	2 3 %
M i a r g n	1 1. 6 %	1 1 0 b p s	1 1. 1 %	1 2 0 b p s

EBIT before special items

For a detailed overview of special items please see the reconciliation tables on slides 26-27.

Conference Call – Q2/15 Results, Fresenius SE & Co. KGaA, Investor Relations © Copyright, July 30, 2015

Cash Flow Development

€ m	O p e r a	i C F t n g		( ) C t a p e n e x		1 F C h F l r e e a s o w
	Q / 2 1 5	L T M M i a r g n	Q / 2 1 5	L T M M i a r g n	Q / 2 1 5	L T M M i a r g n
	2 7 1	1 3 9 %	7 9 -	6 3 % -	1 9 2	7 6 %
	1 1 7	1 0 6 %	5 1 -	4 7 % -	6 6	3 5 9 %
	7 -	0 8 %	6 -	% 1 1 -	3 1 -	0 3 % -
/ Co te rp or a O he t r	1 0 -	n a	2 -	n a	1 2 -	n a
C l. F M ex c	3 7 1	2 % 1 1 7	1 3 8 -	% 5 2 -	2 3 3	2 % 6 5
Gr ou p	2 0 7	9 % 1 1	3 3 2 -	4 % 5 -	3 8 8	6 % 5

1 Before acquisitions and dividends

2 Margin incl. FMC dividend

3 Understated: 6.8% excluding €53 million of capex commitments from acquisitions

Conference Call – Q2/15 Results, Fresenius SE & Co. KGaA, Investor Relations © Copyright, July 30, 2015

Fresenius Group: Increased Outlook for Fresenius Kabi

		O l d	N e w
F i r e s e n u s K b i a	l h S t i a e s g o r w o r g a n c h E B I T t t t g r o w c o n s a n c u r r e n c y	4 % 7 % – % % 1 1 1 4 –	6 % 8 % – 8 % 2 % 1 1 –
i F r e s e n s u H l i e o s	l h S t i a e s g r o w o g a n c r l h S t d t a e s g o r w r e p o r e E B I T	3 % 5 % – 6 % 9 % – 3 0 0 € 6 6 5 m –
i F r e s e n u s V d a m e	l h S t i a e s g o r w o r g a n c h E B I T t g r o w	l d i i i % t s n g e g – % 0 % 5 1 –

Fresenius Group: Increased Earnings Guidance

	O l d	N e w
h R t e e n e g o v u r w t t t a c o n s a n c e n c u r r y	% 0 % 7 1 ‒	8 % 0 % 1 ‒
1 h N i t t e n c o m e g o r w t t t o n n e n a c s a c u r r c y	3 % 6 % 1 1 –	8 % 2 % 1 1 –

1 Net income attributable to shareholders of Fresenius SE& Co.KGaA; 2015 before integration costs for hospitals of Rhön-Klinikum AG (~€10 m before tax), before costs for efficiency program at Fresenius Kabi (~€100 m before tax) and disposal gains from the divestment of two HELIOS hospitals (€34 m before tax); 2014 before special items

Attachments

Fresenius Group: Overview – Calculation of Noncontrolling Interest

€ m	/ H 1 1 5	/ F Y 1 4
b f d l l E i i i t t t t a n n g s e o e a a n n o n c o n o n g n e e s r r x r r	1 4 7 8 ,	2 5 1 2 ,
T a x e s	2 4 7 -	0 0 7 -
f l l i i h N t t t, t o n c o n o n g n e e s e e o r r r	0 9 4 -	7 4 5 -
i d i l C i F M t t r e s e n u s e c a a r e n e n c o m e n o b b l ( Q 2 / 9 ) i F i 1 5 6 % t t t t a r u a e o r e s e n u s : ~	2 9 7 -	2 5 4 -
l l h l d d l N i i i F i M i C t t t o n c o n o n g n e e s o e s n e s e n s e c a a e r r r r u r \$ ( / S 2 d d l H 1 1 5 U 1 4 i t F i M i : m a c c o r n g o r e s e n u s e c a 's l ) C F i i S t t t a r e n a n c a a e m e n s	1 1 0 -	1 6 1 -
l l h l d b N i i i F i K i t t t o n c o n o n g n e e s o e s n e s e n s a r r r r u ( € ), i l i ( € ) d d 1 4 F H 4 t m r e s e n u s e o s m a n u e o - - d 's 2 3 l h ( 2 ) F i V % i € t r e s e n u s a m e e x e r n a o w n e r s p m -	2 0 -	4 2 -
b b l N i i F i S E & C K G A t t t t t e n c o m e a r u a e o r e s e n u s o a	6 4 2	1 0 6 7 ,

Fresenius Group: Cash Flow

€ m	Q / 2 1 5	M M L T i a r g n	Q / 2 1 4	M M L T i a r g n	G h t r o w Y Y o
O i C h l F t p e r a n g a s o w	7 2 0	% 1 1 9	6 1 0	% 1 0 1	% 1 8
C ( ) t a p e x n e	3 3 2 -	% 5 4 -	2 8 9 -	% 5 5 -	% 1 5 -
F C h F l r e e a s o w ( b f i i i d d i i d d ) t e o r e a c q u s o n s a n v e n s	3 8 8	6 5 %	3 2 1	4 6 %	2 1 %
i i i ( ) A t t c q s o n s n e u	6 1 -		1 6 1 -		6 2 %
d d D i i v e n s	4 7 6 -		4 2 9 -		1 1 % -
F C h F l r e e a s o w ( f i i i d d i i d d ) t t a e r a c q u s o n s a n v e n s	1 4 9 -	0 1 %	2 6 9 -	1 4 9 % -	4 5 %

Margin = in % of sales

Cash Flow Development LTM

€ m	O t p e r a	i C F n g	C a p e x	( ) t n e	1 F C h F l r e e a s o w
	/ L T M H 1 1 5	L T M M in a rg	/ L T M H 1 1 5	/ L T M H 1 1 5	/ L T M H 1 1 5	L T M M in a rg
	7 8 0	1 3 9 %	3 5 4 -	6 3 % -	4 2 6	7 6 %
	8 5 4	0 6 % 1	2 6 1 -	% 4 7 -	3 2 3	3 9 % 5
	9	0 8 %	1 2 -	1 1 % -	3 -	0 3 % -
Co / te rp or a O t he r	2 4 -	n a	1 1 -	n a	3 5 -	n a
l. C F M ex c	1 3 4 9 ,	2 1 1 7 %	6 3 8 -	5 2 % -	7 1 1	2 6 5 %
Gr ou p	3 0 8 6 ,	% 1 1 9	1 3 9 6 - ,	% 5 4 -	1 6 9 0 ,	% 6 5

1 Before acquisitions and dividends

2 Margin incl. FMC dividend

3 Understated: 6.8% excluding €53 million of capex commitments from acquisitions

Conference Call – Q2/15 Results, Fresenius SE & Co. KGaA, Investor Relations © Copyright, July 30, 2015

Margin = in % of sales

Fresenius Group: Leverage Ratio

1Pro forma acquisitions; before special items

2Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG; before special items

3Before special items; without major acquisitions

Fresenius Kabi: Strong Organic Sales Growth

€ m	Q / 2 1 5	O i r g a n c G h t r o w Q 2 Y Y o	/ H 1 1 5	O i r g a n c G h t r o w H 1 Y Y o
I. V D r u g s	6 6 4	2 8 %	9 1 1 1 ,	% 1 7
l l C i i N i i t t n c a u r o n	4 0 0	7 %	7 7 2	8 %
f h I i T n o n e p u s r a y	2 3 7	0 %	6 8 4	0 %
d l / i i M D e c a e c e s v f h l T i T a n s s o n e c n o o g r u y	2 5 5	2 % -	0 5 1	% 1 -
T l l t o a s a e s	1 5 3 8 ,	1 1 %	2 9 3 2 ,	8 %

Fresenius Kabi: Strong Organic Sales Growth

€ m	/ Q 2 1 5	O i r g a n c G h t r o w Q 2 Y Y o	/ H 1 1 5	O i r g a n c G h t r o w H 1 Y Y o
E o p e u r	3 5 4	% 5	0 2 1 5 ,	% 5
h N A i t o m e c a r r	5 5 3	2 4 %	1 0 2 6 ,	1 3 %
f A i P i i s a a c c -	2 9 6	4 %	5 6 4	4 %
/ f L i A i A i t a n m e r c a r c a	1 5 5	% 1 4	2 9 0	% 1 1
T l l t o a s a e s	3 8 1 5 ,	% 1 1	2 9 3 2 ,	8 %

Fresenius Helios: Sales Growth

€ m	Q / 2 1 5	G h t r o w Q 2 Y Y o	/ H 1 1 5	G h t r o w H 1 Y Y o
f b l h d l l E i i i i t t s a s e n p o o o c c r	1 3 2 0 ,	2 %	2 8 3 5 ,	3 %
A i i i t q s o n s c u ( l d ) i i 1 t < c o n s o a o n y r	6 3		1 9 1
T l l t o a s a e s	1 3 8 3 ,	7 %	2 7 7 4 ,	1 0 %

Fresenius Helios: Performance Indicators

	H / 1 1 5	H / 1 1 4	C h a n g e
1 f h l N i t o o o s p a s l A t i i c u e c a r e c n c s - l P t- t i i o s a c u e c a r e c n c s -	1 1 1 8 7 2 4	1 1 0 8 6 2 4	1 % % 1 0 %
1 f b d N o o e s A l i i t c u e c a r e c n c s - l i i P t- t o s a c u e c a r e c n c s -	3 4 3 9 1 , 2 9, 2 1 8 3 5, 1 7	3 4 1 8 8 , 2 9, 0 6 8 2 0 5, 1	1 % 1 % % 1
d A i i m s s o n s ( ) A i i t t t c u e c a r e n p a e n -	5 9 7, 8 2 0	5 5 7, 8 2 0	7 %
O c c u p a n c y P t- t o s a c u e c a r e -	8 1 %	8 2 %
f l h ( d ) A t t e g e e n g o v r a s a y a y s 2 A t e a e c u c r - P t- t o s a c u e c a r e -	6. 5 2 6. 7	6. 6 2 6. 8

1December 31, 2014

2German average (2013): 7.5

Fresenius Helios: Sales Influence Hospital Acquisitions / Divestitures

i i i A t c q u s o n s	l i d l A n n u a z e s a e s
l f H i t o s p a s r o m h l k R ö K i i n n u m -	b € 1 9 n ~	l d d f 7 0 % i t c o n s o a e a s o ~ J 1 2 0 1 4 a n u a r y ,
		l d d f 2 0 % i t c o n s o a e a s o ~ h M 1 2 0 1 4 a c r ,
		l d d f S i H K t c o n s o a e a s o 3 0 2 0 J 1 4 n e u ,
	€ 0 4 m ~	C h l d d f i t u x a v e n c o n s o a e a s o 2 0 A 1 1 4 t u g u s ,
k h l D i e o z e n	€ 8 m ~	l d d f i t c o n s o a e a s o l A i 1 2 0 1 5
D i i t t v e s u r e s		p r ,
l k i H t B Z o s p a s o n a e n a r w u ,	€ 9 0 m ~	l d d f i D t e c o n s o a e a s o b 2 0 F 1 1 4 e a r u r y ,

Fresenius Vamed: Strong Sales Growth

€ m	Q / 2 1 5	G h t r o w Q 2 Y Y o	H / 1 1 5	G h t r o w H 1 Y Y o
b P j i t r o e c u s n e s s S b i i e r v c e u s n e s s	1 2 2 3 3 1	3 1 % % 1 7	2 0 2 2 6 1	1 7 % 6 % 1
l l T t o a s a e s	2 5 5	2 3 %	6 3 4	6 % 1
l T E B I T t o a M i a g n r	9 3. % 5	0 % -8 0 b p s	1 6 3. % 5	7 % -3 0 b p s
1 d k O i t r e r n a e 1 d b k l O r e r a c o g	9 2	0 % 5 -	2 8 4 9 1 4 7 ,	% 5 - 2 6 %

Project business only

December 31, 2014

Fresenius Group: Key Figures According to IFRS

€ m	/ H 1 1 5 S G U A A P	/ H 5 I 1 1 S F R
l S a e s	1 3 4 2 9 ,	1 3 6 2 2 ,
1 E B I T	8 2 2 1 ,	8 9 1 1 ,
N i t t t e n e r e s	3 3 0 -	3 3 0 -
2 N i t e n o m e c	6 2 4	6 3 4
3 i N t e n c o m e	6 2 4	6 2 9
h f l O i C t p e a n g a s o r w	1 2 1 5 ,	1 2 5 7 ,
l h l B t t t a a n c e s e e o a	4 2 2 7 1 ,	4 2 3 7 0 ,

Before special items

2Net income attributable to shareholders of Fresenius SE & Co. KGaA

Net income attributable to shareholders of Fresenius SE & Co. KGaA, before special items

Reconciliation according to U.S. GAAP – Q2 2015 / Q2 2014

The Group's U.S. GAAP financial results as of June 30, 2015 and June 30, 2014 comprise special items. Net income attributable to shareholders of Fresenius SE& Co.KGaA was adjusted for these special items. The table below shows the special items and the reconciliation from net income (before special items) to earnings according to U.S. GAAP.

€m	Q2 /2 01 5 be for e ial ite sp ec ms	eff ici en cy pro gra m	int ion rat eg fo sts co r ire d ac qu Rh ön ho ita ls sp	Q2 /2 01 5 rd ing to ac co U.S . G AA P ( inc l. s cia l pe ) ite ms	Q2 /2 01 4 be for e ial ite sp ec ms	al Fe nw int ion rat eg sts co	int ion rat eg fo sts co r ire d ac qu Rh ön ho ita ls sp	dis l g ain po sa fro Rh ön m ke sta	Q2 /2 01 4 rd ing to ac co U.S . G AA P ( inc l. s cia l pe ) ite ms
Sa le s	6, 9 4 6			6, 9 4 6	5, 5 2 1				5, 5 2 1
E B I T	9 7 1	-3 0	-6	9 3 5	7 6 0	-2	-8	3 5	7 8 5
l In te t r t re s es u	-1 6 5			-1 6 5	-1 4 5				-1 4 5
Ne in be fo t ta co m e re xe s	8 0 6	-3 0	-6	7 7 0	6 1 5	-2	-8	3 5	6 4 0
In ta co me xe s	-2 3 4	9	2	-2 2 3	-1 9 9	1	2	-1	-1 9 7
Ne in t co m e	5 7 2	-2 1	-4	5 4 7	4 1 6	-1	-6	3 4	4 4 3
Le l l ing in tro te t ss no nc on re s	-2 2 2			-2 2 2	-1 5 7				-1 5 7
Ne in i bu b le t t tr ta co m e a ha ho l de f to s re rs o Fr iu S E Co K Ga A & es en s	3 5 0	- 2 1	-4	3 2 5	2 5 9	-1	-6	3 4	2 8 6

The special items are reported in the Group Corporate/Other segment.

Reconciliation according to U.S. GAAP – H1 2015 / H1 2014

The Group's U.S. GAAP financial results as of June 30, 2015 and June 30, 2014 comprise special items. Net income attributable to shareholders of Fresenius SE& Co.KGaA was adjusted for these special items. The table below shows the special items and the reconciliation from net income (before special items) to earnings according to U.S. GAAP.

€m	/2 H1 01 5 be for e ial sp ec ite ms	eff ici en cy pro gra m	int rat ion eg sts fo co r ire d ac qu Rh ön ho ita ls sp	dis l po sa ins fr ga om tw o LIO S HE ho ita ls sp	/2 H1 01 5 rd ing ac co to U.S GA AP ( inc l. ial sp ec ) ite ms	/2 H1 01 4 be for e ial sp ec ite ms	Fe al nw int rat ion eg sts co	int rat ion eg sts fo co r ire d ac qu Rh ön ho ita ls sp	dis l po sa ins fr ga om tw o LIO S HE ho ita ls sp	dis l po sa in fro ga m Rh ön ke sta	/2 H1 01 4 rd ing ac co to U.S . G AA P ( inc l. ial sp ec ) ite ms
Sa le s	1 3, 4 2 9				1 3, 4 2 9	1 0, 7 3 3					1 0, 7 3 3
E B I T	1, 8 2 2	-4 0	-8	3 4	1, 8 0 8	1, 4 0 3	-3	-8	2 2	3 5	1, 4 4 9
l In te t r t re s es u	-3 3 0				-3 3 0	-2 8 3					-2 8 3
Ne in be fo t ta co m e re xe s	9 2 1, 4	-4 0	-8	3 4	8 1, 4 7	2 1, 1 0	-3	-8	2 2	3 5	1, 1 6 6
In ta co me xe s	-4 4 1	1 2	2		-4 2 7	-3 3 2	1	2	-1	-1	-3 3 1
Ne in t co m e	1, 0 5 1	-2 8	-6	3 4	1, 0 5 1	7 8 8	-2	-6	2 1	3 4	8 3 5
Le l l ing in tro te t ss no nc on re s	-4 0 9				-4 0 9	-3 0 1					-3 0 1
Ne t in t tr i bu ta b le co m e a ha ho l de f to s re rs o Fr iu S E Co K Ga A & es en s	6 4 2	-2 8	-6	3 4	6 4 2	4 8 7	-2	-6	2 1	3 4	5 3 4

The special items are reported in the Group Corporate/Other segment.

Share Information

Share key facts

Number of shares¹ 543,478,807 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Depositary bank Deutsche Bank

Ratio 4 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Exchange OTCQX International Premier Structure Sponsored Level I ADR

1As of June 30, 2015

Financial Calendar 2015

29.10.2015 Report on 3rd quarter 2015

Please note that these dates could be subject to change.

Contact

k M G i a s e o g r u r	l S V P I R i t t n e s o e a o n s v r F i S E & C K G A r e s e n u s o a	l l L i I t e s e g e n	l V P I R i t t n e s o e a o n s v r F i S E & C K G A r e s e n u s o a
h p o n e : l i e -m a :	9 6 2 6 0 8 2 8 4 1 7 4 5 + - k G @ f M i i a r u s. e o r g r e s e n u s. c o m	h p o n e : l i e -m a :	9 6 2 6 0 8 8 4 1 7 4 4 7 + - l l @ f L i I t i e s e g e n r e s e n u s. c o m

For further information and current news: http://www.fresenius.com